



# Ibrance® (Palbociclib) Prior Authorization Form

Member Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_ Member ID#: \_\_\_\_\_

## Drug Information

Pharmacy billing (NDC: \_\_\_\_\_) Start Date (or date of next dose): \_\_\_\_\_  
Dose: \_\_\_\_\_ Regimen: \_\_\_\_\_

## Billing Provider Information

Provider NPI: \_\_\_\_\_ Provider Name: \_\_\_\_\_  
Provider Phone: \_\_\_\_\_ Provider Fax: \_\_\_\_\_

## Prescriber Information

Prescriber NPI: \_\_\_\_\_ Prescriber Name: \_\_\_\_\_  
Prescriber Phone: \_\_\_\_\_ Prescriber Fax: \_\_\_\_\_ Specialty: \_\_\_\_\_

## Criteria

**For Initial Authorization (Initial approval will be for the duration of 6 months):**

1. Please indicate the diagnosis and information:

**Breast Cancer**

- A. Is diagnosis advanced, metastatic disease? Yes \_\_\_ No \_\_\_
- B. Is disease human epidermal receptor type 2 (HER2)-negative? Yes \_\_\_ No \_\_\_
- C. Is disease hormone receptor positive? Yes \_\_\_ No \_\_\_
- D. Will palbociclib be used in combination with an aromatase inhibitor for a female?  
Yes \_\_\_ No \_\_\_
- E. Will palbociclib be used in combination with fulvestrant for a female with disease progression following endocrine therapy? Yes \_\_\_ No \_\_\_
- F. Will palbociclib be used in combination with an aromatase inhibitor or fulvestrant for a male?  
Yes \_\_\_ No \_\_\_

**If answer is none of the above, please indicate diagnosis:** \_\_\_\_\_

Additional Information: \_\_\_\_\_

### For Continued Authorization:

1. Date of last dose: \_\_\_\_\_
2. Does member have any evidence of progressive disease while on palbociclib (when used for metastatic disease only)? Yes \_\_\_ No \_\_\_
3. Has the member experienced any adverse drug reactions related to palbociclib therapy?  
Yes \_\_\_ No \_\_\_

*If yes, please specify adverse reactions:* \_\_\_\_\_

Additional Information: \_\_\_\_\_

**Prescriber Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

***I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge.***

*Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.*

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy  
Pharmacy Management Consultants  
Product Based Prior Authorization Unit

Fax: 1-800-224-4014  
Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

*This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.*